Vaxcyte, Inc.

As of June 30, 2026, Vaxcyte, Inc. carries a market capitalization of 6.98B, placing it among publicly traded companies globally. Its enterprise value stands at 5.78B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Vaxcyte, Inc.'s next confirmed earnings release is scheduled for November 9, 2026.

As of June 30, 2026, Vaxcyte, Inc. has 136.89M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Vaxcyte, Inc. maintains a current ratio of 5.72, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Vaxcyte, Inc. posted a negative return on equity (ROE) of -36.51, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -33.03, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 483.75, a quick read on workforce productivity versus industry peers.

As of the close on October 6, 2026, Vaxcyte, Inc.'s stock has gained approximately 67.13% over the past 52 weeks. The 50-day moving average sits at 51.53, while the 200-day moving average is 47.85.

Over the twelve months ended June 30, 2026, Vaxcyte, Inc. generated - - in revenue and converted that into -931.55M in net income, yielding earnings per share of -7.05. EBITDA reached -996.54M, while operating income came in at -1.02B.

As of June 30, 2026, Vaxcyte, Inc. holds 1.30B in cash and equivalents against 101.05M in total debt, resulting in a net debt position of -160.35M. Total book value stands at 2.41B, with working capital of 1.12B providing operational flexibility.

Vaxcyte, Inc. produced -771.34M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -34.87M in capital expenditures, free cash flow totaled -806.21M - equivalent to -6.10 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -11.97: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -7.60, meaning Vaxcyte, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Vaxcyte, Inc. has an Altman Z-Score of 10.62, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.